ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AbbVie and Regenxbio are partnering to develop RGX-314, a gene therapy in clinical trials for eye diseases. AbbVie will pay Regenxbio $370 million up front and up to $1.38 billion more. RGX-314 is intended to be a one-time therapy for wet age-related macular degeneration. The treatment uses a viral vector to carry the genetic information for part of a monoclonal antibody that blocks a growth factor tied to the formation of leaky blood vessels.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter